1LEVER R, PAGE C P. Novel drug development opportunities for heparin [ J ]. Nat Rev Drug Discov,2002,1 (2) : 140-148.
2GOMES O M, GOMES E S. Dipyridamole and low doses of heparin as a new successful physiopathologic and therapeutic approach in 2 cases of disseminated intravascular coagulation [J]. Heart Surg Forum,2010,13 ( 1 ) :E49-E51.
3GRAY E, MULLOY B, BARROWCLIFFE T W. Heparin and low- molecular- weight heparin [ J ]. Thromb Haemost, 2008,99 (5) :807-818.
4MU E, DING R, AN X, et al. Heparin attenuates lipopolysac- charide-induced acute lung injury by inhibiting nitric oxide synthase and TGF- beta/Smad signaling pathway [ J ]. Thromb Res,2012,129(4) :479-485.
5YOUNG E. The anti-inflammatory effects of heparin and relat- ed compounds [ J ]. Thromb Res, 2008,122 ( 6 ) : 743- 752.
6WANG M, HE J, MEI B, et al. Therapeutic effects and anti-in- flammatory mechanisms of heparin on acute lung injury in rab- bits [ J]. Acad Emerg Med ,2008,15 (7) :656-663.
7LUO J, CAO J, JIANG X, et al. Effect of low molecular weight heparin rectal suppository on experimental ulcerative colitis in mice [ J ]. Biomed Pharmacother,2010,64 (7) :441-445.
8LAKSHMI T S, SHANMUGASUNDARAM N, SHANMUGA- NATHAN S, et al. Efficacy of desulfated heparin mitigating in- flammation in rat burn wound model[ J ]. J Biomed Mater Res B Appl Biomater,2011,97 (2) : 215- 223.
9PATEL B, GUPTA N, AHSAN F. Low- molecular- weight hepa- rin(LMWH)-loaded large porous PEG-PLGA particles for the treatment of asthma [ J ]. J Aerosol Med Pulm Drug Deliv, 2014,27( 1 ) :12-20.
10ZHAO D, DING R, MAO Y, et al. Heparin rescues sepsis- as- sociated acute lung injury and lethality through the suppres- sion of inflammatory responses [ J ]. Inflammation, 2012,35.(6) :1825-1832.
2YE RG, LU ZY. In Science [M]. 6th edition. Beijing: People's Medical Publishing Press, 2005: 86-91. Chinese.
3HUANG SW, WANG HL. Clinical Application of Heparin [M]. Zhengzhou: Henan Medical University Press, 1999: 1-2. Chinese.
4XIE X, RIVIER AS, ZAKRZEWICZ A, et al. Inhibition of se- lectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides [J]. J Biol Chem, 2000, 275(44): 34818-34825.
5I HOU JJ, ZHU L. Interleukin-8 and chronic obstructive pulmonary disease[J]. Section of Respiratory System Foreign Medical Sciences, 2005, 25(6): 427-429. Chinese.
6BHOWNNIK A, SEEMUNGAL TA, SAPSFORD R J, et al. Relation of sputum inflammatory markers to symptoms and lung fun- tion changes in COPD exacerbations [J]. Thorax, 2000, 55 (2): 114-120.
7YUAN ZM. Interleukin-6 and respiratory disease. Section of Respiratory System Foreign Medical Sciences, 1997, 17(1): 33.Chinese.
8JONES H, PAUL W, PAGE CP. The elects otlaeparin and relat- ed molecules on vascular permeability and neutrophil accumulation in rabbit skin[J]. Br J Pharmacol, 2002, 135(2): 469--479.
9BAO XJ. Heparin anti-inflammatory anti-fibrosis research [J]. Clinical and Experimental Medicine, 2007, 6 (1): 163-164. Chinese.
10SAIAS A, SANS M, SORIANO A, et al. Heparin attenuates TNF-alpha induced inflammatory response through a CDllb dependent mechanism[J]. Gut, 2000, 47(1): 88-96.
